Clinical trials: Healthy, Postmenopausal Women
Osteoporosis
Effects of Proteins Fraction Derived From Milk on Osteoporosis Prevention
Osteoporosis is defined as a systemic skeletal disease characterised by low bone mass and microarchitectural deterioration of bone tissue, with a consequent increase in bone fragility and susceptibility to fracture.
- Trial name
- NCT01478724
- Testing
- Milk proteins fraction
- Where
- France
- Volunteers
- 291 people, healthy volunteers welcome
- Sponsor
- Soredab
Myocardial Infarction, Stroke
Women's Health Initiative Strong and Healthy Study
The WHISH trial applies state-of-the science behavioral principles and currently available technologies to deliver a physical activity intervention without face-to-face contact to ~25,000 older U.S. women expected to consent.
- Conditions
- Myocardial Infarction, Stroke, Cardiovascular Mortality, Hip Fractures
- Trial name
- WHISH (NCT02425345)
- Testing
- Physical Activity
- Volunteers
- 49,331 people, healthy volunteers welcome
- Sponsor
- Fred Hutchinson Cancer Center
Healthy Volunteers
A Study of ACE-2494 in Healthy Subjects
The purpose of the study is to assess safety, tolerance, pharmacokinetic, and pharmacodynamics of single doses of ACE-2494 in healthy postmenopausal women.
- Trial name
- NCT03478319
- Where
- Canada
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Healthy
GLPG0492 Pharmacodynamics
GLPG0492 is a selective androgen receptor modulator: the compound should help protect against (or help restore) muscle loss in case of immobilization (e.g.
- Trial name
- NCT01538420
- Testing
- GLPG0492
- Where
- Belgium
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Lakefront Biotherapeutics NV
Healthy
Food Study of Letrozole Tablets 2.5 mg and Femara® Tablets 2.5 mg
The objective of this study was to investigate the bioequivalence of Mylan's letrozole 2.5 mg tablets to Novartis' Femara® 2.5 mg tablets following a single, oral 2.5 mg (1 x 2.5 mg) dose administered under fed conditions.
- Trial name
- NCT00648154
- Testing
- Letrozole Tablets 2.5 mg, Femara® Tablets 2.5 mg
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Mylan Pharmaceuticals Inc
Breast Cancer Survivors, Postmenopause
Resistance-type Exercise Training in Postmenopausal Women Survivors of Breast Cancer
Background: In postmenopausal women, an alteration in body composition occurs as a consequence of the secretion of low levels of serum estrogens by the ovaries.
- Conditions
- Breast Cancer Survivors, Postmenopause, Resistance Training
- Trial name
- MUSCLE-CLIM (NCT05690295)
- Testing
- Prolonged resistance-type exercise training
- Where
- Chile
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Universidad de La Frontera
Normal Hepatic Function, Impaired Hepatic Function
Effect of Hepatic Impairment on LDE225..
This study is to evaluate the pharmacokinetics and safety of 800 mg of LDE225 in subjects with impaired hepatic function and healthy subjects with normal hepatic function.
- Trial name
- NCT01764776
- Testing
- LDE225
- Where
- 5 sites in United States, Belgium and 3 more
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Food-effect
Effect of Food on the Bioavailability of 30 mg Estetrol (E4) Tablet in Healthy Postmenopausal Female Volunteers
Assessment of the effect of a high fat meal on the quantity in blood of a female sex hormone called estetrol (E4). The study also aims at determining how subject tolerate the study drug and how safe it is for them.
- Trial name
- NCT03798197
- Testing
- 30 mg estetrol (E4)
- Where
- Bulgaria
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Donesta Bioscience
Postmenopause
Study Evaluating Potential Drug Interaction Of Bazedoxifene & Premarin In Healthy Postmenopausal Women
Bazedoxifene (BZA) 20 mg tablet is an investigational medication (not approved by FDA) which is being studied for possible prevention and treatment of postmenopausal osteoporosis.
- Trial name
- NCT00706225
- Testing
- Bazedoxifene and conjugated estrogens
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Perimenopausal Women, Postmenopausal Female Patients
Female-Specific Modifiers for Healthy Early Action in Cardiovascular Risk Trajectories
Cardiovascular disease is the leading cause of death in women, yet risk is systematically underestimated and preventive interventions are often initiated too late.
- Conditions
- Perimenopausal Women, Postmenopausal Female Patients, Cardiovascular (CV) Risk
- Trial name
- FEM-HEART (NCT07703124)
- Testing
- Personal training, App-based physical intervention
- Volunteers
- 605 people, healthy volunteers welcome
- Sponsor
- Ludwig Boltzmann Institute for Cardiovascular Research
Hypoactive Sexual Desire Disorder
Lybridos in Pre-and Postmenopausal Women With Hypoactive Sexual Desire Disorder
A double-blind, randomized, placebo-controlled, dose-finding study to investigate the safety and efficacy of Lybridos in the domestic setting in healthy female subjects with hypoactive sexual desire disorder and maladaptive…
- Trial name
- NCT02101203
- Testing
- 0.5 mgTestosterone + 10 mg Buspirone
- Where
- 10 sites in United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Emotional Brain NY Inc.
Mammographic Breast Density
Effect of Aspirin on Mammogram Density in Healthy Postmenopausal Women With a Moderate or High Level of Breast Density
RATIONALE: Aspirin may be effective in reducing breast density in healthy postmenopausal women with a moderate or high level of breast density.
- Trial name
- NCT00470561
- Testing
- Aspirin
- Where
- United States
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- Fred Hutchinson Cancer Center
Postmenopause
To Evaluate the Impact of Smoking on PK After Single-dose Oral Administration of GS1-144 Tablets .
A Drug-Drug Interaction Study to Evaluate the Effect of Smoking (CYP1A2 Inducer) on the Pharmacokinetics Following a Single Oral Dose of GS1-144 Tablets in Chinese Healthy Postmenopausal Female Trial Participants
- Trial name
- NCT07534176
- Testing
- GS1-144 tablets
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Healthy, Osteopenia
Resistance Training and Rapamycin to Enhance Bone Formation in Postmenopausal Women
The aim of the present clinical trial is to examine the effects of everolimus, resistance training, or their combination on bone and muscle health formation in elderly women aged 60-75 years.
- Conditions
- Healthy, Osteopenia, Osteoporosis Risk
- Trial name
- StrongBone (NCT07191353)
- Testing
- Everolimus, Resistance training
- Where
- 2 sites in Denmark
- Volunteers
- 148 people, healthy volunteers welcome
- Sponsor
- Odense University Hospital
Breast Cancer
A Study to Assess the Mass Balance of [14C]HRS-8080 in Healthy Chinese Postmenopausal Female Subjects.
This single-part, healthy volunteer study will try to identify how the test medicine is taken up, broken down and removed from the body.
- Trial name
- NCT07320521
- Testing
- [14C]HRS-8080
- Where
- China
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Epilepsy
Study of Excretion Balance and Pharmacokinetics of [14C]-Sodium Valproate (3.7 MBq) in Healthy Postmenopausal or Permanently Sterile Female Subjects
Primary Objectives: To determine the excretion balance and systemic exposure of radioactivity after oral administration of [14C]-sodium valproate (VPA) .
- Trial name
- NCT03681158
- Testing
- sodium valproate
- Where
- United Kingdom
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
A Research Study Looking Into the Effect of Semaglutide and NNC0480 0389 on Blood Levels of a Birth Control Pill in Woman After Menopause
Novo Nordisk is developing a combination therapy with the investigational drug NNC0480-0389 and an already approved medicine called "semaglutide" for the treatment of type-2 diabetes (T2D).
- Trial name
- NCT05153564
- Testing
- Semaglutide 1.34 mg/mL, Semaglutide 3.0 mg/mL, NNC0480-0389 10 mg/mL
- Where
- Germany
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Healthy
Calcium Retention as Influenced by Dietary Components That Induce an Acid Load
The impact of protein sources such as beef as part of Western diet on calcium retention remains controversial. We propose to test the hypothesis that the positive effect of high protein intake (especially from meat protein) can…
- Trial name
- NCT00620763
- Testing
- High Meat - High Potential Renal Acid Load (PRAL) diet, Low Protein - Low Potential Renal Acid Load (PRAL) diet
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- USDA Grand Forks Human Nutrition Research Center
Vulvovaginal Atrophy, Vasomotor Symptoms
A Phase 1, Open-Label, Parallel Group Study to Evaluate the Pharmacokinetics and Safety of DARE-HRT1 in Healthy PostMenopausal Women
An open-label study to assess the PK of estradiol, estrone and progesterone from the DARE-HRT1 intravaginal rings at two different dose strengths.
- Trial name
- NCT05418426
- Testing
- IVR Dose 1, IVR Dose 2, Oral Reference
- Where
- 2 sites in Australia
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Daré Bioscience, Inc.
Menopause, Cardiovascular Risk Factor
Effect of 4 Weeks of Citrulline and Glutathione Supplementation on Arterial Function
Examining the effects of 4 weeks of Citrulline alone or in combination with glutathione on the arterial function of postmenopausal women.
- Trial name
- NCT04672447
- Testing
- L-Citrulline, Glutathione
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Texas Tech University